Evidence map›Paper›PMID 40481496›Full record

ArticleDiabetology & metabolic syndrome2025

Serum metabolic profiling in diabetic kidney disease patients using ultra-high performance liquid chromatography-tandem mass spectrometry.

Bin Zhang, Chunmei Dai, Jiuyi Jiang, Jun Wang, Yuwei Yang, Jiafu Feng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bin Zhang *Department of Medical Laboratory, The Affiliated Hospital, Southwest Medical University, Luzhou, 646000, China.
Chunmei Dai *Department of Medical Laboratory, The Affiliated Hospital, Southwest Medical University, Luzhou, 646000, China.
Jiuyi JiangDepartment of Medical Laboratory, The Affiliated Hospital, Southwest Medical University, Luzhou, 646000, China.
Jun WangDepartment of Laboratory Medicine, Sichuan Provincial Women's and Children's Hospital, The Affiliated Women's and Children's Hospital of Chengdu Medical College, Chengdu, 610045, China.
Yuwei YangDepartment of Clinical Laboratory, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, 621000, China.
Jiafu FengDepartment of Medical Laboratory, The Affiliated Hospital, Southwest Medical University, Luzhou, 646000, China. jiafufeng@sc-mch.cn.

Funding

Medical Association of Sichuan Province S22017Mianyang Central Hospital 2022YJ003Mianyang Central Hospital 2022YJ006Science and Technology Department of Sichuan Province 2021YJ0239
6 · The paper itself

Abstract

backgroundDiabetic kidney disease (DKD) remains one of the leading causes of end-stage renal failure. The currently available diagnostic and classification markers, such as the urinary albumin-to-creatinine ratio and estimated glomerular filtration rate, demonstrate inadequate precision in forecasting the onset and progression of DKD. This study aims to investigate the serum metabolic profile of patients with DKD, with the objective of identifying reliable biomarkers that can enhance the prediction of the transition from diabetes mellitus (DM) to DKD and distinguishing DKD from nondiabetic kidney disease (NDKD).

methodsUntargeted metabolomic analysis was performed on serum samples obtained from 53 DKD patients, 54 NDKD patients, 59 individuals diagnosed with simple diabetes mellitus (SDM), and 56 healthy controls utilizing ultra-high performance liquid chromatography-tandem mass spectrometry. Differential metabolites among the groups were identified, metabolic pathways were investigated, and the diagnostic efficacy of selected metabolites was evaluated.

resultsThe metabolic enrichment pathways shared between DKD and NDKD encompassed glycerophospholipid metabolism, glycerolipid metabolism, and tryptophan metabolism. In contrast, pyrimidine metabolism and arginine biosynthesis were uniquely enriched in DKD. Compared to the NDKD group, significantly elevated levels of phosphatidylglycerol (PG, 14:0) and D-Maltose were observed in DKD patients. Additionally, in comparison to the SDM group, the DKD group exhibited significant increases in lysophosphatidic acid (LPA, 16:3), LPA (18:5), LPA (22:5), phosphatidic acid (PA, 18:3), PG (26:4), L-Glutamine, Uridine, Cytidine, Formyl-N-acetyl-5-methoxykynurenamine, 2-Oxoadipate, Thymidine, L-Citrulline, and 5-Hydroxy-L-tryptophan, while PG (28:4) levels were markedly reduced. Among these, Uridine, Cytidine, Thymidine, and L-Citrulline were associated with pyrimidine metabolism, whereas L-Glutamine and L-Citrulline participated in the arginine biosynthesis pathway. Furthermore, the differential metabolites exhibited varying degrees of correlation with renal function indicators in DKD patients.

conclusionsPG (14:0) and D-Maltose may help distinguish DKD from NDKD, while L-Glutamine, Uridine, Cytidine, Thymidine, and L-Citrulline are linked to the progression from DM to DKD. Larger studies are needed to validate these findings and assess their diagnostic and causal significance.

Indexed as

Candidate biomarkersDiabetic kidney diseaseMetabolic pathway analysisUltra-high performance liquid chromatography-tandem mass spectrometryUntargeted metabolomics

Identifiers

PMID40481496
PMCPMC12144808

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.